Amyris Inc. (AMRS) stock lost 9.31% in the extended trading session after losing 7..46% in the morning session on Tuesday, April 7, 2021. AMRS shares have risen by 560.27% over the last 12 months, and they have moved down by -15.73% in the past week. Over the past three months, the stock has gained 110.35%, while over the past six months, it has added 430.50%.
Proposed public offering of common stock
On April 7, 2021, Amyris, Inc. announced the initiation of a proposed underwritten public offering of shares of its common stock.
It’s a resale of the $150.0 million of shares stock on the behalf of its current stockholders, DSM International B.V. and Vivo Capital LLC. Amyris will not receive any proceeds and it is looking to offer 100.0 million shares of its common stock.
Additional $37.5 million of shares are expected to be available to underwriters in 30 days.
Partnership with Reese Witherspoon
On April 7, 2021, Amyris, Inc. signed a 5-year partnership with Reese Witherspoon as global brand ambassador for Biossance, one of the fastest-growing clean and sustainable skincare brands in the world.
The partnership will shape the future of clean beauty with the global leadership of Reese Witherspoon and with unparalleled expertise of Biossance in skincare efficacy, and clean beauty science.
Participation at Cowen’s 2nd Annual Consumer Platforms
Amyris recently participated in a fireside chat at Cowen’s 2nd Annual Consumer Platforms for the Next Generation Summit which held on Tuesday, April 6th at 9:30 am ET.
Hosting the upcoming third webinar
On April 1, 2021, Amyris said that it will host the third webinar in its virtual investor mini-series themed “Delivering on the Promise of Synthetic Biology.”
The third webinar will be conducted via live webcast and teleconference on Thursday, April 22, 2021, at 1:00 pm ET (10:00 am PT) followed by a business update and end with a Q&A session.
Agreement with DSM Nutritional Products Ltd
On March 31, 2021, Amyris signed an agreement with DSM Nutritional Products Ltd to supply Amyris’s product portfolio of flavour and fragrance (F&F) ingredients exclusively.
The total agreement value is estimated at over $500 million and Amyris will continue to develop, scale and manufacture future molecules with its existing partners and DSM.
Record production of CBG
March 25, 2021, Amyris, Inc said that AMRS stock has set a record delivery f production of Cannabigerol (CBG) from fermentation for consumer skincare treatment formulations.
There is no news except the public offering of its common stock which could be the reason behind its sinking on Tuesday. The record shows that AMRS performed well and this negativity will be over soon.